Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
2.894 USD +9.42% Intraday chart for Finch Therapeutics Group, Inc. +5.62% -19.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Decliners MT
North American Morning Briefing : Stocks Seen -2- DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Finch Therapeutics Group, Inc. Announces Resignation of Nicholas Haft as Member of Board CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Index CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Value Index CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Value Index CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Index CI
Top Premarket Decliners MT
Finch Therapeutics Group Slumps Almost 15% in Premarket Tuesday MT
Finch Therapeutics Group to Implement 1-for-30 Reverse Stock Split MT
Finch Therapeutics Group, Inc. Enters into Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC CI
Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Posts Q1 Revenue $107,000 MT
Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023 CI
Finch Therapeutics Appoints Matthew Blischak CEO, Lance Thibault CFO MT
Finch Therapeutics Group, Inc. Announces Executive Leadership Transitions CI
Finch Therapeutics Group, Inc. Appoints Lance Thibault as Chief Financial Officer, Effective May 16, 2023 CI
Finch Therapeutics Group, Inc. Announces Executive Changes CI
Finch Therapeutics Reports Clinical Collaboration in Ulcerative Colitis; Shares Soar After-Hours MT
Finch Therapeutics Group, Inc. Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement CI
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Posts Q4 Revenue $8,000 MT
Chart Finch Therapeutics Group, Inc.
More charts
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company's assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn's disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Finch Therapeutics Group, Inc. - Nasdaq
  4. News Finch Therapeutics Group, Inc.
  5. Finch Therapeutics Secures two US Patents for Microbiome Therapeutic Product to Treat Autism Spectrum Disorder